Skip to main content
SpringerLink
Log in

Malignes Melanom

  • Chapter
Therapiekonzepte Onkologie

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Garbe C (1997) Epidemiologie des Hautkrebses. In: Garbe C, Dummer R, Kaufmann R, Tilgen W (Hrsg) Dermatologische Onkologie. Berlin, Heidelberg, New York, Tokio: Springer, S 40–56

    Chapter  Google Scholar 

  2. Garbe C, Thieß S, Nürnberger F et al. (1991) Incidence and mortality of malignant melanoma in Berlin (West) from 1980 to 1986. Acta Derm Venereol (Stockh) 71: 506–511

    CAS  Google Scholar 

  3. MacKie RM, Freudenberger T, Aitchison TC (1989) Personal risk-factor chart for cutaneous melanoma. Lancet ii:487–490

    Article  Google Scholar 

  4. Garbe C (1992) Sonne und malignes Melanom. Hautarzt 43:251–257

    PubMed  CAS  Google Scholar 

  5. Garbe C, Orfanos CE (1992) Epidemiology of malignant melanoma in Central Europe. Risk Factors and prognostic predictors. Pigment Cell Res 5(Suppl 2): 285–294

    Google Scholar 

  6. Garbe C, Weiss J, Krüger S et al. (1993) The German Melanoma Registry and environmental risk factors implied. Recent Results Cancer Res 128:69–89

    Article  PubMed  CAS  Google Scholar 

  7. Garbe C, Büttner P, Weiß J et al. (1994) Risk factors for developing cutaneous malignant melanoma and criteria for identification of persons at risk. Multicenter Case Control Study of the German Central Malignant Melanoma Registry. J Invest Dermatol 102:695–699

    Article  PubMed  CAS  Google Scholar 

  8. Garbe C, Büttner P, Weiß J et al. (1994) Associated factors to the prevalence of > 50 common melanocytic nevi, atypical melanocytic nevi and actinic lentigines. Multicenter Case Control Study of the German Central Malignant Melanoma Registry. J Invest Dermatol 102:700–705

    Article  PubMed  CAS  Google Scholar 

  9. Garbe C, Büttner P, Bertz J, Burg G, d’Hoedt B et al. (1995) Primary cutaneous melanoma: Identification of prognostic groups in 5093 patients and estimation of individual prognosis. Cancer 75:2484–2491

    Article  PubMed  CAS  Google Scholar 

  10. Ketcham AS, Moffat FL, Balch CM (1992) Classification and staging. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Philadelphia: JB Lippincott, pp 165–187

    Google Scholar 

  11. UICC (1987) TNM Klassifikation maligner Tumoren. 4. Aufl. Hermanek P, Scheibe O, Spiessl B, Wagner G (Hrsg) Berlin, Heidelberg, New York, Tokyo: Springer

    Google Scholar 

  12. UICC (1997) TNM Classification of malignant tumours. 5th ed. Sobin LH, Wittekind C (eds), New York: John Wiley & Sons

    Google Scholar 

  13. Häffner AC, Garbe C, Büttner P, Orfanos CE, Rassner G, Burg G (1992) The prognosis of primary and metastasizing melanoma. An evaluation of the TNM classification in 2495 patients and proposals for their revision. Br J Cancer 66:856–861

    Article  PubMed  Google Scholar 

  14. Orfanos CE, Jung HG, Rassner G, Wolff HH, Garbe C (1994) Stellungnahme und Empfehlungen der Kommission Malignes Melanom der Deutschen Dermatologischen Gesellschaft zur Diagnostik, Behandlung und Nachsorge des Malignen Melanoms der Haut — Stand 1993/94. Hautarzt 45:285–291

    Article  PubMed  CAS  Google Scholar 

  15. Garbe C (1996) Primäre Diagnostik, Ausbreitungsdiagnostik und Prognoseschätzung des malignen Melanoms. Onkologe 2:441–448

    Article  Google Scholar 

  16. Kaufmann R, Tilgen W, Garbe C (1997) Malignes Melanom. In: Garbe C (Hrsg) Diagnostische und therapeutische Standards in der Dermatologischen Onkologie. Qualitätssicherung in der Onkologie 5.2. München: Zuckschwerdt S 33–47

    Google Scholar 

  17. Ackerman AB, Scheiner AM (1983) How wide and deep is wide and deep enough? A critique of surgical practice in excision of primary cutaenous malignant melanoma. Human Pathol 14:743–744

    Article  CAS  Google Scholar 

  18. Veronesi U, Cascinelli N, Adamus J et al. (1988) Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. N Engl JMed 318:1159–1162

    Article  CAS  Google Scholar 

  19. Veronesi U, Cascinelli N (1991) Narrow excision (1cm margin): a safe procedure for thin cutaneous melanoma. Arch Surg 126:438–441

    Article  PubMed  CAS  Google Scholar 

  20. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, Jeweli TJ, Bartolucci AA, Mihm MC, Barnhill R, Wanebo HJ (1993) Efficacy of 2 cm surgical margins for intermediate-thickness melanomas (1–4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 218:262–269

    Article  PubMed  CAS  Google Scholar 

  21. Ho VC, Sober AJ (1990) Therapy for cutaneous melanoma: An update. J Am Acad Dermatol 22:159–176

    Article  PubMed  CAS  Google Scholar 

  22. Kaufmann R (1996) Operative Therapie des primären Melanoms. Onkologe 2: 449–452

    Article  Google Scholar 

  23. Veronesi U, Adamus J, Bandiera DC et al. (1982) Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities. Cancer 49:2420–2430

    Article  PubMed  CAS  Google Scholar 

  24. Balch CM, Milton GW, Cascinelli N, Sim HF (1992) Elective Lymph node dissection: pros and cons. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Philadelphia: JB Lippincott, pp 345–366

    Google Scholar 

  25. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC et al. (1996) Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224:255–263

    Article  PubMed  CAS  Google Scholar 

  26. Drepper H, Köhler CO, Bastian B et al. (1993) Benefit of elective node dissection in subgroups of melanoma patients — results of a multicenter study in 3616 patients. Cancer 72:741–749

    Article  PubMed  CAS  Google Scholar 

  27. Drepper H, Köhler CO, Bastian B et al. (1994) Prognosevorteil für definierte Risikogruppen durch die Lymphknotendissektion. Langzeitstudie an 3616 Melanom -patienten. Hautarzt 45:615–622

    Article  PubMed  CAS  Google Scholar 

  28. Panizzon R, Alber R, Schnyder UW (1990) Die dermatologische Radiotherapie des Melanoms der Haut mit besonderer Berücksichtigung des Lentigo-maligna Melanoms. In Orfanos CE, Garbe C (Hrsg.) Das maligne Melanom der Haut, Zuckschwerdt Verlag, München, S 232–235

    Google Scholar 

  29. Veronesi U, Adamus J, Aubert C et al. (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. New Engl J Med 307:913–916

    Article  PubMed  CAS  Google Scholar 

  30. Lejeune FJ (1987) Phase III adjuvant studies in operable malignant melanoma (review). Anticancer Res 7:701–706

    PubMed  CAS  Google Scholar 

  31. Hauschild A, Sterry W (1992) Adjuvante Therapie des malignen Melanoms. Dtsch Med Wochenschr 117:303–306

    Article  PubMed  CAS  Google Scholar 

  32. Tilgen W (1994) Adjuvante und palliative Therapie des Melanoms. Eine Standortbestimmung. Chirurg 65:153–163

    PubMed  CAS  Google Scholar 

  33. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7–17

    PubMed  CAS  Google Scholar 

  34. Ames FC, Balch CM, Reintgen D (1992) Local recurrences and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Philadelphia: JB Lippincott, pp 287–294

    Google Scholar 

  35. Singletary SE, Balch CM (1992) Recurrent regional metastases and their management. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Philadelphia: JB Lippincott, pp 427–435

    Google Scholar 

  36. Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS (1992) Adjuvant chemotherapy in malignant melanoma using dacarbazine, carmustine, cisplatin, and tamoxifen: a University of South Florida and H. Lee Mofrîtt Melanoma Center Study. Ann Plast Surg 28:60–64

    Article  PubMed  CAS  Google Scholar 

  37. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K (1994) Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vin-desine improves survival. Cancer 73:2119–2130

    Article  PubMed  CAS  Google Scholar 

  38. Pectasides D, Alevizakos N, Bafaloukos D et al. (1994) Adjuvant chemotherapy with dacarbazine, vindesine, and cisplatin in pathological stage II malignant melanoma. Am J Clin Oncol 17:55–59

    Article  PubMed  CAS  Google Scholar 

  39. Karakousis CP, Velez A, Driscoll DL, Takita H (1994) Metastasectomy in malignant melanoma. Surgery 115:295–302

    PubMed  CAS  Google Scholar 

  40. Göhl J, Meyer T, Haas C, Altendorf Hofmann A, Hohenberger W (1996) 1st die chirurgische Therapie von Fernmetastasen maligner Melanome sinnvoll? Langen-becks Arch Chir Suppl Kongressbd 113:122–126

    Google Scholar 

  41. Burmeister BH, Smithers BM, Poulsen M, McLeod GR, Bryant G, Tripcony L, Thorpe C (1995) Radiation therapy for nodal disease in malignant melanoma. World J Surg 19:369–371

    Article  PubMed  CAS  Google Scholar 

  42. Sack H (1996) Strahlentherapie des Melanoms. Der Onkologe 2:473–475

    Article  Google Scholar 

  43. Houghton AN, Legha S, Bajorin DF (1992) Chemotherapy for metastatic melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ (eds) Cutaneous melanoma. Philadelphia: JB Lippincott, pp 498–508

    Google Scholar 

  44. Garbe C (1993) Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma. Melanoma Res 3:291–299

    PubMed  CAS  Google Scholar 

  45. Constanzi JJ, Vaitkevicius VK, Quagliana JM et al. (1975) Combination chemotherapy for disseminated malignant melanoma. Cancer 35:342–346

    Article  Google Scholar 

  46. Carter RD, Krementz ET, Hill GJ et al. (1976) DTIC (NSC-45388) and combination therapy for melanoma. I. Studies with DTIC, BCNU (NSC-409962), CCNU (NSC-79037), vincristine (NSC-67574), and hydroxyurea (NSC-32065). Cancer Treat Rep 60:601–609

    PubMed  CAS  Google Scholar 

  47. Constanzi JJ, Fletcher WS, Balcerzak SP et al. (1984) Combination chemotherapy plus levamisole in the treatment of disseminated malignant melanoma. Cancer 53:833–836

    Article  Google Scholar 

  48. Seigler HF, Lucas VS Jr., Pickett NJ et al. (1980) DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. Cancer 46:2346–2348

    Article  PubMed  CAS  Google Scholar 

  49. Ahn SS, Giuliano A, Kaiser L et al. (1983) The limited role of BOLD chemotherapy for disseminated malignant melanoma. Proc Am Soc Clin Oncol 2:228, C-893

    Google Scholar 

  50. Jose DG, Minty CCJ, Hillcoat BL (1985) Treatment of patients with disseminated malignant melanoma with bleomycin, Oncovin, lomustine and DTIC (BOLD). First international conference on skin melanoma, may 6–9, Venice, abstract 151

    Google Scholar 

  51. York RM, Foltz AT (1988) Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma. Cancer 61:2183–2186

    Article  PubMed  CAS  Google Scholar 

  52. The Prudente Foundation Melanoma Study Group (1989) Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). Cancer 63:1676–1680

    Google Scholar 

  53. Gundersen S (1987) Dacarbazine, vindesine, and cisplatin combination chemotherapy in advanced malignant melanoma: a phase II study. Cancer Treat Rep 71:997–999

    PubMed  CAS  Google Scholar 

  54. Verschraegen CF, Kleeberg UR, Mulder J et al. (1988) Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. Cancer 62:1061–1065

    Article  PubMed  CAS  Google Scholar 

  55. Legha SS, Ring S, Papadopoulos N et al. (1989) A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) vor metastatic melanoma. Cancer 64:2024–2029

    Article  PubMed  CAS  Google Scholar 

  56. Del Prête SA, Maurer LH, O’Donnell J et al. (1984) Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 68:1403–1405

    PubMed  Google Scholar 

  57. Richards JM, Gilewski TA, Ramming K et al. (1992) Effective chemotherapy for melanoma after treatment with interleukin-2. Cancer 69:427–429

    Article  PubMed  CAS  Google Scholar 

  58. Saba HI, Cruse CW, Wells KE, Klein CJ, Reintgen DS (1992) Treatment of stage IV malignant melanoma with a platinol based combination chemotherapy regiment: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Ann Plast Surg 28:65–69

    Article  PubMed  CAS  Google Scholar 

  59. Saba HI, Klein CJ, Reintgen DS (1993) Management of advanced stage IV metastatic melanoma with dacarbazine, carmustine, cisplatin, and tamoxifen regimens: a University of South Florida and H. Lee Moffitt Melanoma Center Study. Proc Annu Meet Am Soc Clin Oncol 121: A1359

    Google Scholar 

  60. McClay EF, Mastrangelo MJ, Berd D, Bellet RE (1992) Effective combination che-mo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer 50:553–556

    Article  PubMed  CAS  Google Scholar 

  61. Jacquillat C, Khayat D, Banzet P et al. (1990) Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol 25:263–266

    Article  PubMed  CAS  Google Scholar 

  62. Hersey P, McLeod RC, Thomson DB (1989) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with dacarbazine (DTIC) in advanced malignant melanoma. J Interferon Res 9 (suppl 2) : 118

    Google Scholar 

  63. Kerr R, Pippen P, Mennel R, Jones S (1989) Treatment of metastatic malignant melanoma with a combination of interferon-alpha-2a (ifn-alpha-2a, Roferon) and dacarbazine (DTIC). Proc Annu Meet Am Soc Clin Oncol 8: A1122

    Google Scholar 

  64. Bajetta E, Negretti E, Giannotti B et al. (1990) Phase II study of interferon-alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13:405–409

    Article  PubMed  CAS  Google Scholar 

  65. Breier S, Pensel R, Rotfe C et al. (1990) High dose DTIC with recombinant human interferon alpha-2b (rhifn2b) for the treatment of metastatic malignant melanoma (MMM). Proc Annu Meet Am Soc Clin Oncol 9:A1090

    Google Scholar 

  66. Mulder NH, Schraffordt-Koops H, Sleijfer DT et al. (1990) Dacarbazine and alpha-interferon for disseminated malignant melanoma. Proc Annu Meet Am Soc Clin Oncol 9: A1083

    Google Scholar 

  67. Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9:1403–1408

    PubMed  CAS  Google Scholar 

  68. Bajetta E, Di Leo A, Zampino EG et al. (1994) Multicenter randomized trial of dacarbazine alone or in combination with different doses and schedules of interferon alpha-2a in the treatment of advanced melanoma. J Clin Oncol 12:806–811

    PubMed  CAS  Google Scholar 

  69. Thomson D, Adena M, McLeod GRC et al (1992) Interferona-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomized trial QMP8704. Proc Annu Meet Am Soc Clin Oncol 11: A1177

    Google Scholar 

  70. Schuchter L, McGuire WP, Wohlganger J, Redden T (1989) Sequential treatment of metastatic melanoma with interferon-alpha (IFN) plus cis-platinum (CDDP). Proc Annu Meet Am Soc Clin Oncol 8: A1120

    Google Scholar 

  71. Oratz R, Dugan M, Walsh C et al. (1989) Phase II trial of r-alpha 2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 8: A1123

    Google Scholar 

  72. Richner J, Cerny T, Loss RA et al. (1990) A phase II study of continuous sc alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma (MM). Proc Annu Meet Am Soc Clin Oncol 9: A1085

    Google Scholar 

  73. Margolin KA, Doroshow JH, Akman SA et al. (1992) Phase II trial of cisplatin and alpha-interferon in advanced malignant melanoma. J Clin Oncol 10:1574–1578

    PubMed  CAS  Google Scholar 

  74. Gundersen S, Flokkmann A (1989) Interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study. Cancer 64:1617–1619

    Article  PubMed  CAS  Google Scholar 

  75. Kellokumpu-Lehtinen P, Nordman E, Toivanen A (1989) Combined interferon and vinblastine treatment of advanced melanoma: Evaluation of the treatment results and the effects of treatment on immunological functions. Cancer Immunol Immunother 28:213–217

    Article  PubMed  CAS  Google Scholar 

  76. Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28:438–441

    Article  PubMed  CAS  Google Scholar 

  77. Garbe C, Zouboulis CC, Stadler R et al (1993) Prolongation of life in stage IV malignant melanoma by combined treatment with rIFN-a-2a and vindesine. Pigment Cell Res 6:278

    Google Scholar 

  78. Vorobiof DA, Bezwoda WR, Ariad S (1993) Vindesine plus interferon a2b vs IFN a2b vs vindesine in the treatment of advanced melanoma. Proc Annu Meet Am Soc Clin Oncol 12: A1338

    Google Scholar 

  79. Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474–485

    Article  PubMed  CAS  Google Scholar 

  80. Dillman RO, Oldham RK, Barth NM et al. (1990) Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 82:1345–1349

    Article  PubMed  CAS  Google Scholar 

  81. Flaherty LE, Redman BG, Chabot GG et al. (1990) A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65:2471–2477

    Article  PubMed  CAS  Google Scholar 

  82. Dummer R, Becker JC, Kahlhammer U et al. (1991) Combined chemo- and immunotherapy using dacarbazine and continuous infusion of interleukin 2 in metastatic malignant melanoma. Results of a phase II clinical trial. Eur J Dermtol 1:201–205

    Google Scholar 

  83. Demchak PA, Mier JW, Robert NJ et al. (1990) Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9:1821–1830

    Google Scholar 

  84. Hamblin TJ, Davies B, Sadullah S, Oskám R, Palmer P, Franks CR (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2(IL-2) and alfa-interferon (IFN). Proc Annu Meet Am Soc Clin Oncol 10: A1029

    Google Scholar 

  85. Legha S, Plager C, Ring S, Eton O et al. (1992) A phase II study of biochemo-therapy using interleukin-2 (IL-2) + Interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC (D) in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11: A1179

    Google Scholar 

  86. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmuno-therapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338–1343

    PubMed  CAS  Google Scholar 

  87. Richards J, Mehta N, Schroeder L, Dordal A (1992) Sequential chemotherapy/ immunotherapy for metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol 11:A1189

    Google Scholar 

  88. Khayat D, Borel C, Tourani JM et al. (1993) Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 11:2173–2180

    PubMed  CAS  Google Scholar 

  89. Kirchner H, Lopez Haenninen M, Fenner M et al. (1993) Chemoimmunotherapy of advanced malignant melanoma with carboplatin and DTIC followed by subcutaneous interleukin-2 and interferon-alpha. Proc Annu Meet Am Soc Clin Oncol 12: A1356

    Google Scholar 

  90. Atkins MB, O’Boyle KR, Sosman JA et al. (1994) Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. J Clin Oncol 12:1553–1560

    PubMed  CAS  Google Scholar 

  91. Ron IG, Mordish Y, Eisenthal A et al. (1994) A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma. Cancer Immunol Immunother 38:379–384

    Article  PubMed  CAS  Google Scholar 

  92. Garbe C, Büttner P, Ellwanger U, Orfanos CE (1995) Die Versorgung des primären Malignen Melanoms der Haut im deutschen Sprachraum in den Jahren 1983 bis 1993. Eine Studie des Zentralregister Malignes Melanom der Deutschen Dermatologischen Gesellschaft. Hautarzt 46:762–770

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Innere Klinik und Poliklinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Universitätsklinikum Essen, Hufelandstraße 55, 45122, Essen, Deutschland

    Siegfried Seeber  & Jochen Schütte  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1998 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Garbe, C. (1998). Malignes Melanom. In: Seeber, S., Schütte, J. (eds) Therapiekonzepte Onkologie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-10493-4_34

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-10493-4_34

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-63821-6

  • Online ISBN: 978-3-662-10493-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation